FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323048478> ?p ?o ?g. }

• W4323048478 abstract "Abstract Background Voriconazole is a second-generation triazole that is used to prevent and treat invasive fungal infections. The purpose of this study was to evaluate the pharmacokinetic equivalency of a test formulation and reference formulation (Vfend®) of Voriconazole. Materials and methods This was a randomized, open-label, single-dose, two-treatment, two-sequence, two-cycle, crossover phase I trial. The 48 subjects were equally divided into 4 mg/kg and 6 mg/kg groups. Within each group, the subjects were randomized 1:1 to the test or reference formulation.. After a 7-day washout period, crossover formulations were administered. The blood samples were collected at 0.5, 1.0, 1.33,1.42,1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, 48.0 h later in the 4 mg/kg group, while at 0.5, 1.0, 1.5, 1.75, 2.0, 2.08, 2.17, 2.33, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0, 48.0 h later in the 6 mg/kg group. The plasma concentrations of Voriconazole were determined by Liquid chromatography-tandem mass spectrometry (LC–MS/MS). The safety of the drug was evaluated. Results The 90% confidence intervals (CIs) of the ratio of geometric means (GMRs) of C max , AUC 0-t , and AUC 0-∞ in both 4 mg/kg and 6 mg/kg groups were within the prespecified bioequivalence limits between 80 ~ 125%. In the 4 mg/kg groups, 24 subjects were enrolled and completed the study. The mean C max was (2.552 ± 0.448) μg/mL, AUC 0-t was (11.875 ± 7.157) h*μg/mL and AUC 0-∞ was (12.835 ± 9.813) h*μg/mL after a single dose of 4 mg/kg test formulation. The mean C max was (2.615 ± 0.464) μg/mL, AUC 0-t was (12.500 ± 7.257) h*μg/mL and AUC 0-∞ was (13.416 ± 9.485) h*μg/mL after a single dose of 4 mg/kg reference formulation. In the 6 mg/kg groups, 24 subjects were enrolled and completed the study. The mean C max was (3.538 ± 0.691) μg/mL, AUC 0-t was (24.976 ± 12.364) h*μg/mL and AUC 0-∞ was (26.212 ± 14.057) h*μg/mL after a single dose of 6 mg/kg test formulation. The mean C max was (3.504 ± 0.667) μg/mL AUC 0-t was (24.990 ± 12.455) h*μg/mL and AUC 0-∞ was (26.160 ± 13.996) h*μg/mL after a single dose of 6 mg/kg reference formulation. Serious adverse event (SAE) was not observed. Conclusion In both 4 mg/kg group and 6 mg/kg group, equivalent pharmacokinetic characteristics that satisfied the criteria of bioequivalence for both test and reference formulations of Voriconazole. Trial registration NCT05330000 (15/04/2022)." @default.
• W4323048478 created "2023-03-04" @default.
• W4323048478 creator A5004735532 @default.
• W4323048478 creator A5005670014 @default.
• W4323048478 creator A5017164999 @default.
• W4323048478 creator A5028833857 @default.
• W4323048478 creator A5030210043 @default.
• W4323048478 creator A5043573259 @default.
• W4323048478 creator A5061817335 @default.
• W4323048478 creator A5062373348 @default.
• W4323048478 creator A5066302919 @default.
• W4323048478 creator A5087981019 @default.
• W4323048478 creator A5090381942 @default.
• W4323048478 creator A5090651584 @default.
• W4323048478 date "2023-03-03" @default.
• W4323048478 modified "2023-10-09" @default.
• W4323048478 title "Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects" @default.
• W4323048478 cites W2013000822 @default.
• W4323048478 cites W2103605637 @default.
• W4323048478 cites W2164270244 @default.
• W4323048478 cites W2190396016 @default.
• W4323048478 cites W2276581170 @default.
• W4323048478 cites W2514632012 @default.
• W4323048478 cites W2562778159 @default.
• W4323048478 cites W2586430873 @default.
• W4323048478 cites W2599532381 @default.
• W4323048478 cites W2912885719 @default.
• W4323048478 cites W2940423093 @default.
• W4323048478 cites W2953189690 @default.
• W4323048478 cites W3003600823 @default.
• W4323048478 cites W3027703215 @default.
• W4323048478 cites W3116583743 @default.
• W4323048478 cites W3118391100 @default.
• W4323048478 cites W3149038127 @default.
• W4323048478 cites W4241472532 @default.
• W4323048478 cites W4292528167 @default.
• W4323048478 doi "https://doi.org/10.1186/s40360-023-00652-3" @default.
• W4323048478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36869387" @default.
• W4323048478 hasPublicationYear "2023" @default.
• W4323048478 type Work @default.
• W4323048478 citedByCount "0" @default.
• W4323048478 crossrefType "journal-article" @default.
• W4323048478 hasAuthorship W4323048478A5004735532 @default.
• W4323048478 hasAuthorship W4323048478A5005670014 @default.
• W4323048478 hasAuthorship W4323048478A5017164999 @default.
• W4323048478 hasAuthorship W4323048478A5028833857 @default.
• W4323048478 hasAuthorship W4323048478A5030210043 @default.
• W4323048478 hasAuthorship W4323048478A5043573259 @default.
• W4323048478 hasAuthorship W4323048478A5061817335 @default.
• W4323048478 hasAuthorship W4323048478A5062373348 @default.
• W4323048478 hasAuthorship W4323048478A5066302919 @default.
• W4323048478 hasAuthorship W4323048478A5087981019 @default.
• W4323048478 hasAuthorship W4323048478A5090381942 @default.
• W4323048478 hasAuthorship W4323048478A5090651584 @default.
• W4323048478 hasBestOaLocation W43230484781 @default.
• W4323048478 hasConcept C112705442 @default.
• W4323048478 hasConcept C126322002 @default.
• W4323048478 hasConcept C142724271 @default.
• W4323048478 hasConcept C16005928 @default.
• W4323048478 hasConcept C204787440 @default.
• W4323048478 hasConcept C27081682 @default.
• W4323048478 hasConcept C2779548794 @default.
• W4323048478 hasConcept C2780690907 @default.
• W4323048478 hasConcept C42404028 @default.
• W4323048478 hasConcept C44249647 @default.
• W4323048478 hasConcept C71839028 @default.
• W4323048478 hasConcept C71924100 @default.
• W4323048478 hasConcept C87813604 @default.
• W4323048478 hasConcept C98274493 @default.
• W4323048478 hasConceptScore W4323048478C112705442 @default.
• W4323048478 hasConceptScore W4323048478C126322002 @default.
• W4323048478 hasConceptScore W4323048478C142724271 @default.
• W4323048478 hasConceptScore W4323048478C16005928 @default.
• W4323048478 hasConceptScore W4323048478C204787440 @default.
• W4323048478 hasConceptScore W4323048478C27081682 @default.
• W4323048478 hasConceptScore W4323048478C2779548794 @default.
• W4323048478 hasConceptScore W4323048478C2780690907 @default.
• W4323048478 hasConceptScore W4323048478C42404028 @default.
• W4323048478 hasConceptScore W4323048478C44249647 @default.
• W4323048478 hasConceptScore W4323048478C71839028 @default.
• W4323048478 hasConceptScore W4323048478C71924100 @default.
• W4323048478 hasConceptScore W4323048478C87813604 @default.
• W4323048478 hasConceptScore W4323048478C98274493 @default.
• W4323048478 hasIssue "1" @default.
• W4323048478 hasLocation W43230484781 @default.
• W4323048478 hasLocation W43230484782 @default.
• W4323048478 hasLocation W43230484783 @default.
• W4323048478 hasLocation W43230484784 @default.
• W4323048478 hasOpenAccess W4323048478 @default.
• W4323048478 hasPrimaryLocation W43230484781 @default.
• W4323048478 hasRelatedWork W1986616381 @default.
• W4323048478 hasRelatedWork W2016376118 @default.
• W4323048478 hasRelatedWork W2033685750 @default.
• W4323048478 hasRelatedWork W2053536280 @default.
• W4323048478 hasRelatedWork W2055974197 @default.
• W4323048478 hasRelatedWork W2061638403 @default.
• W4323048478 hasRelatedWork W2086164686 @default.
• W4323048478 hasRelatedWork W2359694218 @default.
• W4323048478 hasRelatedWork W2365820484 @default.
• W4323048478 hasRelatedWork W3145656073 @default.

• next